Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.05 |
---|---|
High | 5.05 |
Low | 4.84 |
Bid | 4.94 |
Offer | 5.25 |
Previous close | 4.74 |
Average volume | 80.00 |
---|---|
Shares outstanding | 315.20m |
Free float | 210.68m |
P/E (TTM) | -- |
Market cap | 12.94bn HKD |
EPS (TTM) | -1.34 HKD |
Data delayed at least 15 minutes, as of Nov 14 2024 08:15 GMT.
More ▼
Press releases
- ASH 2024 | Results From Three Clinical Studies of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral Report
- ASH 2024 | Studies of Olverembatinib Selected for Presentations, Including an Oral Report, for the Seventh Consecutive Year
- Registrational Phase III Studies of APG-2449 Cleared by China CDE for the Treatment of Patients with NSCLC
- Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation
- ESMO 2024 | Ascentage Pharma to Present Updated Data of Olverembatinib in Patients with SDH-Deficient GIST during a Mini Oral Presentation at the 2024 ESMO Congress
- Ascentage Pharma Announces 2024 Interim Results
More ▼